Association of depressive symptoms with sweat chloride variability and medication possession ratio during long-term Elexacaftor/Tezacaftor/Ivacaftor therapy in adolescents and young adults with cystic fibrosis. (PubMed, Front Pediatr) - Sep 16, 2026 - "A substantial proportion of patients screened positive for depressive symptoms, which was associated with increased long-term variability in sweat chloride and declining MPR but not lung function. Structured psychological monitoring and targeted interventions may be essential to support adherence and long-term treatment success."
Journal • CNS Disorders • Cystic Fibrosis • Depression • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Psychiatry • Pulmonary Disease • Respiratory Diseases • Transplantation • Type 1 Diabetes Mellitus
|
|
Anika Nader; Anne Moeser; Katja Erler; Mariya Pavlova; Michael Lorenz
|